Human platelets secrete the plasma type of platelet-activating factor acetylhydrolase primarily associated with microparticles

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 26, Issue 8, 2006, Pages 1907-1913

  Mitsios, John V ^a   Vini, Maria P ^a   Stengel, Dominique ^b   Ninio, Ewa ^b   Tselepis, Alexandros D ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b INSERM   (France)

Author keywords

Atherosclerosis; Inflammation; PAF; PAF acetyhydrolase; PMPs

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; MESSENGER RNA; ISOENZYME;

ARTICLE; ATHEROSCLEROSIS; CELL MEMBRANE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOSOL; ENZYME ACTIVITY; ENZYME LOCALIZATION; ENZYME MECHANISM; ENZYME RELEASE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; PARTICLE SIZE; PATHOPHYSIOLOGY; PERIPHERAL CIRCULATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RNA ANALYSIS; THROMBOCYTE; THROMBOCYTE ACTIVATION; WESTERN BLOTTING; BLOOD; ENZYMOLOGY; GENETICS; INTRACELLULAR MEMBRANE; ULTRASTRUCTURE;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; BLOOD PLATELETS; CYTOSOL; HUMANS; INTRACELLULAR MEMBRANES; ISOENZYMES; PARTICLE SIZE; PLATELET ACTIVATION; RNA, MESSENGER;

EID: 33746850259     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000228821.79588.ef     Document Type: Article

References (43)

1. Zimmerman GA, McIntyre TM, Prescott SM, Stafforini DM. The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis. Crit Care Med. 2002;30:S294-301.
2. Pinkard RN, Ludewig JC, McManus LM. Platelet-Activating Factors. New York, NY: Raven Press; 1988.
3. Touqui L, Hatmi M, Vargaftig BB. Human platelets stimulated by thrombin produce platelet-activating factor (1-O-alkyl-2-acetyl-sn-glycero-3- phosphocholine) when the degrading enzyme acetyl hydrolase is blocked. Biochem J. 1985;229:811-816.
4. Tselepis AD, Chapman MJ. Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase. Atheroscler Suppl. 2002;3:57-68.
5. Asano K, Okamoto S, Fukunaga K, Shiomi T, Mori T, Iwata M, Ikeda Y, Yamagushi K. Cellular source(s) of platelet-activating-actor acetylhydrolase activity in plasma. Biochem Biophys Res Commun. 1999;261:511-514.
6. Stafforini DM, Elstad MR, McIntyre TM, Zimmerman GA, Prescott SM. Human macrophages secrete platelet-activating acetylhydrolase. J Biol Chem. 1990;265:9682-9687.
7. Macphee CH, Moores K, Boyd H, Dhanak D, Ife RJ, Leach CA, Leake DS, Milliner KJ, Patterson RA, Suckling KE, Tew DG, Hickey DM. Lipoprotein- associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem J. 1999;338:479-487.
8. Stremler KE, Stafforini DM, Prescott SM, McIntyre TM. Human plasma platelet-activating factor acetylhydrolase. Oxidatively fragmented phospholipids as substrates. J Biol Chem. 1991;266:11095-11103.
9. Arai H, Koizumi H, Aoki J, Inoue K. Platelet-activating factor acetylhydrolase (PAF-AH). J Biochem. 2002;131:635-640.
10. Hattori M, Arai H, Inoue K. Purification and characterization of bovine brain platelet-activating factor acetylhydrolase. J Biol Chem. 1993;268:18748-18753.
11. Rice SQJ, Southan C, Boyd HF, Terrett JA, Macphee CH, Moores K, Gloger IS, Tew DG. Expression, purification and characterization of a human serine-dependent phospholipase A2 with high specificity for oxidized phospholipids and platelet activating factor. Biochem J. 1998;330:1309-1315.
12. Korth R, Bidault J, Palmantier R, Benveniste J, Ninio E. Human platelets release a PAF-acether: acetylhydrolase similar to that in plasma. Lipids. 1993;28:193-199.
13. Iwamoto S, Kawasaki T, Kambayashi J, Ariyoshi H, Monden M. Platelet microparticles: a carrier of platelet-activating factor? Biochem Biophys Res Commun. 1996;218:940-944.
14. Iwamoto S, Kawasaki T, Kambayashi J, Ariyoshi H, Shinoki N, Sakon M, Ikeda Y, Monden M. The release mechanism of platelet-activating factor during shear-stress induced platelet aggregation. Biochem Biophys Res Commun. 1997;239:101-105.
15. Miyazaki Y, Nomura S, Miyake T, Kagawa H, Kitada C, Taniguchi H, Komiyama Y, Fujimura Y, Ikeda Y, Fukuhara S. High shear stress can initiate both platelet aggregation and shedding of procoagulant containing microparticles. Blood. 1996;88:3456-3464.
16. Barry OP, Pratico D, Lawson JA, FitzGerald GA. Transcellular activation of platelets and endothelial cells by bioactive lipids in platelet microparticles. J Clin Invest. 1997;99:2118-2127.
17. Barry OP, Fitzgerald GA. Mechanisms of cellular activation by platelet microparticles. Thromb Haemost. 1999;82:794-800.
18. Horstman LL, Ahn YS. Platelet microparticles: a wide-angle perspective. Crit Rev Oncol Hematol. 1999;30:111-142.
19. Freyssinet JM. Cellular microparticles: what are they bad or good for? J Thromb Haemost. 2003;1:1655-1662.
20. Nomura S, Suzuki M, Katsura K, Xie GL, Miyazaki Y, Miyake T, Kido H, Kagawa H, Fukuhara S. Platelet-derived microparticles may influence the development of atherosclerosis in diabetes mellitus. Atherosclerosis. 1995;116:235-240.
21. Dentan C, Tselepis AD, Chapman MJ, Ninio E. Pefabloc, 4-[2-aminoethyl]benzenesulfonyl fluoride, is a new, potent nontoxic and irreversible inhibitor of PAF-degrading acetylhydrolase. Biochim Biophys Acta. 1996;1299:353-357.
22. Terashita Z, Imura Y, Nishikawa K. Inhibition by CV-3988 of the binding of [3H]-platelet activating factor (PAF) to the platelet. Biochem Pharmacol. 1985;34:1491-1495.
23. Tselepis AD, Dentan C, Karabina S-A, Chapman MJ, Ninio E. PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma: Catalytic characteristics and relation to the monocyte-derived enzyme. Arterioscler Thromb Vasc Biol. 1995;15:1764-1773.
24. Hattori K, Hattori M, Adachi H, Tsujimoto M, Arai H, Inoue K. Purification and characterization of platelet-activating factor acetylhydrolase II from bovine liver cytosol. J Biol Chem. 1995;270:22308-22313.
25. Tselepis AD, Karabina SA, Stengel D, Piedagnel R, Chapman MJ, Ninio E. N-linked glycosylation of macrophage-derived PAF-AH is a major determinant of enzyme association with plasma HDL. J Lipid Res. 2001;42:1645-1654.
26. Taub R, Gould RJ, Garsky VM, Ciccarone TM, Hoxie J, Friedman PA, Shattil SJ. A monoclonal antibody against the platelet fibrinogen receptor contains a sequence that mimics a receptor recognition domain in fibrinogen. J Biol Chem. 1989;264:259-265.
27. Sims PJ, Wiedmer T, Esmon CT, Weiss HJ, Shattil SJ. Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. Studies in Scott syndrome: an isolated defect in platelet procoagulant activity. J Biol Chem. 1989;264:17049-17057.
28. Tsujinaka T, Kajiwara Y, Kambayashi J, Sakon M, Higuchi N, Tanaka T, Mori T. Synthesis of a new cell penetrating calpain inhibitor (calpeptin). Biochem Biophys Res Commun. 1988;153:1201-1208.
29. George JN, Thoi LL, McManus LM, Reimann TA. Isolation of human platelet membrane microparticles from plasma and serum. Blood. 1982;60:834-840.
30. Bernal-Mizrachi L, Jy W, Jimenez JJ, Pastor J, Mauro LM, Horstman LL, de Marchena E, Ahn YS. High levels of circulating endothelial microparticles in patients with acute coronary syndromes. Am Heart J. 2003;145:962-970.
31. George JN. Platelet immunoglobulin G: its significance for the evaluation of thrombocytopenia and for understanding the origin of alpha-granule proteins. Blood. 1990;76:859-870.
32. Del Conde I, Shrimpton CN, Thiagarajan P, Lopez JA. Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation. Blood. 2005;106:1604-1611.
33. Lindemann S, Tolley ND, Dixon DA, McIntyre TM, Prescott SM, Zimmerman GA, Weyrich AS. Activated platelets mediate inflammatory signaling by regulated interleukin 1beta synthesis. J Cell Biol. 2001;154:485-490.
34. Holme PA, Solum NO, Brosstad F, Egberg N, Lindahl TL. Stimulated Glanzmann's thrombasthenia platelets produced microvesicles. Microvesiculation correlates better to exposure of procoagulant surface than to activation of GPIIb-IIIa. Thromb Haemost. 1995;74:1533-1540.
35. Baj-Krzyworzeka M, Majka M, Pratico D, Ratajczak J, Vilaire G, Kijowski J, Reca R, Janowska-Wieczorek A, Ratajczak MZ. Platelet-derived microparticles stimulate proliferation, survival, adhesion, and chemotaxis of hematopoietic cells. Exp Hematol. 2002;30:450-459.
36. VanWijk MJ, VanBavel E, Sturk A, Nieuwland R. Microparticles in cardiovascular diseases. Cardiovasc Res. 2003;59:277-287.
37. Prescott SM, McIntyre TM, Zimmerman G. Inflammation: Basic Principles and Clinical Correlates. Philadelphia, Pa: Lippincott/Williams & Wilkins; 1999.
38. Prescott SM, Zimmerman GA, Stafforini DM, McIntyre TM. Platelet-activating factor and related lipid mediators. Annu Rev Biochem. 2000;69:419-445.
39. Tate DA, Bode AP, Nichols TC, Dehmer GJ. Platelet activation detected by platelet-derived microparticles in coronary sinus blood from patients with unstable coronary syndromes. Circulation. 1992;86:820. Abstract.
40. Mallat Z, Benamer H, Hugel B, Benessiano J, Steg PG, Freyssinet JM, Tedgui A. Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation. 2000;101:841-843.
41. Goudevenos J, Tselepis AD, Vini MP, Michalis L, Tsoukatos DC, Elisaf M, Ninio E, Sideris DA. Platelet-associated and secreted PAF-acetylhydrolase activity in patients with stable angina: sequential changes of the enzyme activity after angioplasty. Eur J Clin Invest. 2001;31:15-23.
42. Brilakis ES, McConnell JP, Lennon RJ, Elesber AA, Meyer JG, Berger PB. Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur Heart J. 2005;26:137-144.
43. Oei HH, van der Meer IM, Hofman A, Koudstaal PJ, Stijnen T, Breteler MM, Witteman JC. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation. 2005;111:570-575.